drugset / Trial / NCT00123279
Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to evaluate the safety and preliminary efficacy of different doses and several exposure times of intravitreal microplasmin in the setting of pars plana vitrectomy for vitreomacular traction maculopathy.
Timeline
- Start
- 2004-12
- Primary completion
- 2007-02
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocriplasmin | Protein / enzyme biologic | 25 ug | Intravitreal |
| Subject | Ocriplasmin | Protein / enzyme biologic | 50 ug | Intravitreal |
| Subject | Ocriplasmin | Protein / enzyme biologic | 75 ug | Intravitreal |
| Subject | Ocriplasmin | Protein / enzyme biologic | 125 ug | Intravitreal |